n'-acetylspermine profile

N'-acetylspermine is a polyamine derivative that has been found to be involved in various biological processes, including cell growth, differentiation, and apoptosis. It is synthesized from spermine by the enzyme spermine acetyltransferase (SAT). N'-acetylspermine has been shown to have anti-tumor activity and is being studied as a potential therapeutic agent for cancer. It is also being investigated for its role in neurodegenerative diseases, such as Alzheimer's disease.
```

N(1)-acetylspermine : An acetylspermine carrying an acetyl group at position N(1). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	916
CHEMBL ID	131004
CHEBI ID	17312
SCHEMBL ID	193116
MeSH ID	M0093932

Synonym
CHEBI:17312 ,
n(1)-acetylspermine
n-[3-({4-[(3-aminopropyl)amino]butyl}amino)propyl]acetamide
25593-72-0
N1-ACETYLSPERMINE ,
C02567
n'-acetylspermine
CHEMBL131004
n-[3-[4-(3-aminopropylamino)butylamino]propyl]acetamide
n-acetylspermine
acetamide, n-(3-((4-((3-aminopropyl)amino)butyl)amino)propyl)-
n'-monoacetylspermine
SCHEMBL193116
GUNURVWAJRRUAV-UHFFFAOYSA-N
acetamide, n-[3-[[4-[(3-aminopropyl)amino]butyl]amino]propyl]-
DTXSID40180274
acetylspermine
n-(3-((4-((3-aminopropyl)amino)butyl)amino)propyl)-acetamide
n1-acspermine
Q3869338
n-(3-((4-((3-aminopropyl)amino)butyl)amino)propyl)acetamide
HY-113200
CS-0059305

Role	Description
human metabolite	Any mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
acetylspermine
acetamides	Compounds with the general formula RNHC(=O)CH3.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (16)

Assay ID	Title	Year	Journal	Article
AID556062	Activity of Encephalitozoon cuniculi polyamine oxidase assessed as hydrogen peroxide release by spectrophotometry	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Metabolism of an alkyl polyamine analog by a polyamine oxidase from the microsporidian Encephalitozoon cuniculi.
AID96307	Compound was determined for spermidine (SPD) level in L1210 cells after treatment at a concentration of 100 uM and expressed as percent compound found in untreated controls.	2003	Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25	Polyamine-iron chelator conjugate.
AID96461	Compound was tested for the growth inhibition of murine L1210 cell at a duration of 48 h	2003	Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25	Polyamine-iron chelator conjugate.
AID162585	Inhibition of SPD uptake by polyamine transporter of MDA-MB-231 breast carcinoma cells	2002	Bioorganic & medicinal chemistry letters, Jan-07, Volume: 12, Issue:1	Synthesis of bis-spermine dimers that are potent polyamine transport inhibitors.
AID556064	Activity of Encephalitozoon cuniculi polyamine oxidase assessed as hydrogen peroxide release per mg protein by spectrophotometry	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Metabolism of an alkyl polyamine analog by a polyamine oxidase from the microsporidian Encephalitozoon cuniculi.
AID96467	Compound was tested for the growth inhibition of murine L1210 cell at a duration of 96 h	2003	Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25	Polyamine-iron chelator conjugate.
AID556067	Activity of Encephalitozoon cuniculi polyamine oxidase assessed as hydrogen peroxide release by spectrophotometry in presence of 1,15-bis{N-[O-phenyl)benzylamino}-4,12-diazapentadecane	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Metabolism of an alkyl polyamine analog by a polyamine oxidase from the microsporidian Encephalitozoon cuniculi.
AID203888	Compound was tested for the enzyme activity against Spermidine/spermine N1-acetyl transferase (SSAT) in murine L1210 cells and expressed as percent compound found in untreated controls.	2003	Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25	Polyamine-iron chelator conjugate.
AID1210039	Drug level in human HepG2 cells assessed as SSAT2-mediated compound formation treated with TETA at 1 mM for 24 hrs	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Metabolism of triethylenetetramine and 1,12-diamino-3,6,9-triazadodecane by the spermidine/spermine-N(1)-acetyltransferase and thialysine acetyltransferase.
AID203885	Compound was tested for the inhibition of spermidine transporter by using [3H]SPD transport in murine L1210 cell	2003	Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25	Polyamine-iron chelator conjugate.
AID101806	Effective concentration of compound with DFMO tested in vitro for ability to inhibit polyamine transport and growth of MDA-MB-231 breast carcinoma cell line	2002	Bioorganic & medicinal chemistry letters, Jan-07, Volume: 12, Issue:1	Synthesis of bis-spermine dimers that are potent polyamine transport inhibitors.
AID1210040	Drug level in human HepG2 cells assessed as SSAT1-mediated compound formation treated with SpmTrien at 100 uM for 24 hrs	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Metabolism of triethylenetetramine and 1,12-diamino-3,6,9-triazadodecane by the spermidine/spermine-N(1)-acetyltransferase and thialysine acetyltransferase.
AID199307	Compound was tested for the enzyme activity against S-Adenosyl-methionine decarboxylase in murine L1210 cells and expressed as percent compound found in untreated controls.	2003	Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25	Polyamine-iron chelator conjugate.
AID96446	Compound was determined for spermine (SPM) level in murine L1210 cells after treatment at a concentration of 100 uM and expressed as percent compound found in untreated controls.	2003	Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25	Polyamine-iron chelator conjugate.
AID150566	Compound was tested for the enzyme activity against ornithine decarboxylase (ODC) in murine L1210 cells and expressed as percent compound found in untreated controls.	2003	Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25	Polyamine-iron chelator conjugate.
AID96305	Compound was determined for putrescine (PUT) level in murine L1210 cells after treatment at a concentration of 100 uM and expressed as percent compound found in untreated controls.	2003	Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25	Polyamine-iron chelator conjugate.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	12 (30.77)	18.7374
1990's	14 (35.90)	18.2507
2000's	6 (15.38)	29.6817
2010's	7 (17.95)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	40 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
gamma-aminobutyric acid gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.. gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.	1.98	1	amino acid zwitterion; gamma-amino acid; monocarboxylic acid	human metabolite; neurotransmitter; Saccharomyces cerevisiae metabolite; signalling molecule
n(1)-acetylspermidine N(1)-acetylspermidine : An acetylspermidine having the acetyl group at the N1-position.	5.15	18	acetylspermidine	Escherichia coli metabolite; metabolite
histamine [no description available]	1.97	1	aralkylamino compound; imidazoles	human metabolite; mouse metabolite; neurotransmitter
putrescine [no description available]	4.77	12	alkane-alpha,omega-diamine	antioxidant; fundamental metabolite
spermidine [no description available]	5.54	27	polyazaalkane; triamine	autophagy inducer; fundamental metabolite; geroprotector
spermine [no description available]	5.82	36	polyazaalkane; tetramine	antioxidant; fundamental metabolite; immunosuppressive agent
pimagedine pimagedine: diamine oxidase & nitric oxide synthase inhibitor; an advanced glycosylation end product inhibitor; used in the treatment of diabetic complications; structure. aminoguanidine : A one-carbon compound whose unique structure renders it capable of acting as a derivative of hydrazine, guanidine or formamide.	1.99	1	guanidines; one-carbon compound	EC 1.14.13.39 (nitric oxide synthase) inhibitor; EC 1.4.3.4 (monoamine oxidase) inhibitor
deferiprone Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.. deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.	2.01	1	4-pyridones	iron chelator; protective agent
eflornithine Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.. eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.	2.9	4	alpha-amino acid; fluoroamino acid	trypanocidal drug
4-amino-5-hexynoic acid 4-amino-5-hexynoic acid: structure	1.96	1
methenamine Methenamine: An anti-infective agent most commonly used in the treatment of urinary tract infections. Its anti-infective action derives from the slow release of formaldehyde by hydrolysis at acidic pH. (From Martindale, The Extra Pharmacopoeia, 30th ed, p173). hexamethylenetetramine : A polycyclic cage that is adamantane in which the carbon atoms at positions 1, 3, 5 and 7 are replaced by nitrogen atoms.	2.01	1	polyazaalkane; polycyclic cage; tetramine	antibacterial drug
trientine Trientine: An ethylenediamine derivative used as stabilizer for EPOXY RESINS, as ampholyte for ISOELECTRIC FOCUSING and as chelating agent for copper in HEPATOLENTICULAR DEGENERATION.. TETA : An azamacrocyle in which four nitrogen atoms at positions 1, 4, 8 and 11 of a fouteen-membered ring are each substituted with a carboxymethyl group.. 2,2,2-tetramine : A polyazaalkane that is decane in which the carbon atoms at positions 1, 4, 7 and 10 are replaced by nitrogens.	2.08	1	polyazaalkane; tetramine	copper chelator
vigabatrin [no description available]	1.96	1	gamma-amino acid	anticonvulsant; EC 2.6.1.19 (4-aminobutyrate--2-oxoglutarate transaminase) inhibitor
carbon tetrachloride Carbon Tetrachloride: A solvent for oils, fats, lacquers, varnishes, rubber waxes, and resins, and a starting material in the manufacturing of organic compounds. Poisoning by inhalation, ingestion or skin absorption is possible and may be fatal. (Merck Index, 11th ed). tetrachloromethane : A chlorocarbon that is methane in which all the hydrogens have been replaced by chloro groups.	1.96	1	chlorocarbon; chloromethanes	hepatotoxic agent; refrigerant
serine Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.. serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.	2.1	1	L-alpha-amino acid; proteinogenic amino acid; serine family amino acid; serine zwitterion; serine	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
cytarabine [no description available]	2	1	beta-D-arabinoside; monosaccharide derivative; pyrimidine nucleoside	antimetabolite; antineoplastic agent; antiviral agent; immunosuppressive agent
ornithine Ornithine: An amino acid produced in the urea cycle by the splitting off of urea from arginine.. ornithine : An alpha-amino acid that is pentanoic acid bearing two amino substituents at positions 2 and 5.	1.96	1	non-proteinogenic L-alpha-amino acid; ornithine	algal metabolite; hepatoprotective agent; mouse metabolite
gold Gold: A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.	2.06	1	copper group element atom; elemental gold
4-chloro-7-nitrobenzofurazan 4-Chloro-7-nitrobenzofurazan: A benzofuran derivative used as a protein reagent since the terminal N-NBD-protein conjugate possesses interesting fluorescence and spectral properties. It has also been used as a covalent inhibitor of both beef heart mitochondrial ATPase and bacterial ATPase.. 4-chloro-7-nitrobenzofurazan : A benzoxadiazole that is 2,1,3-benzoxadiazole which is substituted at position 4 by chlorine and at position 7 by a nitro group.	1.98	1	benzoxadiazole; C-nitro compound; organochlorine compound	EC 1.4.3.4 (monoamine oxidase) inhibitor; EC 3.6.1.3 (adenosinetriphosphatase) inhibitor; fluorescent probe; fluorochrome
glutamic acid Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.. glutamic acid : An alpha-amino acid that is glutaric acid bearing a single amino substituent at position 2.	2.1	1	glutamic acid; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; ferroptosis inducer; micronutrient; mouse metabolite; neurotransmitter; nutraceutical
mdl 27695 MDL 27695: structure given in first source	2.05	1
n-acetylputrescine N-acetylputrescine : An N-monoacetylalkane-alpha,omega-diamine that is the N-monoacetyl derivative of putrescine.	2.66	3	N-monoacetylalkane-alpha,omega-diamine; N-substituted putrescine	metabolite; mouse metabolite
n(8)-acetylspermidine N(8)-acetylspermidine : An acetylspermidine that is 1,8-diamino-4-azaoctane in which one of the hydrogens of the amino group attached to C-8 is replaced by an acetyl group.	3.8	4	acetylspermidine	Escherichia coli metabolite; human metabolite
1-methylspermidine 1-methylspermidine: RN & structure given in first source; RN given refers to parent cpd	2.01	1
n',n''-diacetylspermine N',N''-diacetylspermine: intermediate in polyamine catabolism	3.23	6	acetamides
n-(gamma-maleimidobutyryloxy)succinimide [no description available]	2.39	2
isoputreanine isoputreanine: metabolite of spermidine; RN given refers to parent cpd or spermine in human urine	1.97	1	organonitrogen compound; organooxygen compound
puromycin [no description available]	1.99	1	puromycins	antiinfective agent; antimicrobial agent; antineoplastic agent; EC 3.4.11.14 (cytosol alanyl aminopeptidase) inhibitor; EC 3.4.14.2 (dipeptidyl-peptidase II) inhibitor; nucleoside antibiotic; protein synthesis inhibitor
mdl 72527 MDL 72527: RN given refers to di-HCl; RN for parent cpd not available 6/85; polyamine oxidase inhibitor	2.41	2
cgp 48664 4-amidinoindan-1-one 2'-amidinohydrazone: structure given in first source	2.4	2
phosphatidylcholines Phosphatidylcholines: Derivatives of PHOSPHATIDIC ACIDS in which the phosphoric acid is bound in ester linkage to a CHOLINE moiety.	1.98	1	1,2-diacyl-sn-glycero-3-phosphocholine
1,12-diamino-3,6,9-triazadodecane 1,12-diamino-3,6,9-triazadodecane: a copper-chelating agent	2.08	1
guanosine triphosphate Guanosine Triphosphate: Guanosine 5'-(tetrahydrogen triphosphate). A guanine nucleotide containing three phosphate groups esterified to the sugar moiety.	1.96	1	guanosine 5'-phosphate; purine ribonucleoside 5'-triphosphate	Escherichia coli metabolite; mouse metabolite; uncoupling protein inhibitor

Condition	Relationship Strength	Studies
Leukemia L 1210 [description not available]	2.9	4
Disease Exacerbation [description not available]	2.21	1
Basedow Disease [description not available]	2.21	1
Central Hypothyroidism [description not available]	2.21	1
Chronic Lymphocytic Thyroiditis [description not available]	2.21	1
Graves Disease A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes (GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy).	2.21	1
Hypothyroidism A syndrome that results from abnormally low secretion of THYROID HORMONES from the THYROID GLAND, leading to a decrease in BASAL METABOLIC RATE. In its most severe form, there is accumulation of MUCOPOLYSACCHARIDES in the SKIN and EDEMA, known as MYXEDEMA. It may be primary or secondary due to other pituitary disease, or hypothalamic dysfunction.	2.21	1
Hashimoto Disease Chronic autoimmune thyroiditis, characterized by the presence of high serum thyroid AUTOANTIBODIES; GOITER; and HYPOTHYROIDISM.	2.21	1
Cancer of Colon [description not available]	2.06	1
Colonic Neoplasms Tumors or cancer of the COLON.	2.06	1
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2.7	3
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	1.96	1
Leucocythaemia [description not available]	1.96	1
Malignant Melanoma [description not available]	1.96	1
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	1.96	1
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	1.96	1
Mesothelioma A tumor derived from mesothelial tissue (peritoneum, pleura, pericardium). It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. (Dorland, 27th ed)	1.96	1
Carbon Tetrachloride Poisoning Poisoning that results from ingestion, injection, inhalation, or skin absorption of CARBON TETRACHLORIDE.	1.96	1
Extravascular Hemolysis [description not available]	1.98	1
Hemolysis The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.	1.98	1
Blood Pressure, Low [description not available]	1.98	1
Hypotension Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.	1.98	1
Hypertrophy General increase in bulk of a part or organ due to CELL ENLARGEMENT and accumulation of FLUIDS AND SECRETIONS, not due to tumor formation, nor to an increase in the number of cells (HYPERPLASIA).	1.99	1
Cerebro-Hepato-Renal Syndrome [description not available]	1.97	1
Zellweger Syndrome An autosomal recessive disorder due to defects in PEROXISOME biogenesis which involves more than 13 genes encoding peroxin proteins of the peroxisomal membrane and matrix. Zellweger syndrome is typically seen in the neonatal period with features such as dysmorphic skull; MUSCLE HYPOTONIA; SENSORINEURAL HEARING LOSS; visual compromise; SEIZURES; progressive degeneration of the KIDNEYS and the LIVER. Zellweger-like syndrome refers to phenotypes resembling the neonatal Zellweger syndrome but seen in children or adults with apparently intact peroxisome biogenesis.	1.97	1
Breast Cancer [description not available]	2.88	1
Breast Neoplasms Tumors or cancer of the human BREAST.	2.88	1

n'-acetylspermine

Description

Cross-References

Synonyms (23)

Roles (1)

Drug Classes (2)

Bioassays (16)

Research

Studies (39)

Market Indicators

Research Demand Index: 10.77

Study Types

n'-acetylspermine

Description

Cross-References

Synonyms (23)

Roles (1)

Drug Classes (2)

Bioassays (16)

Research

Studies (39)

Market Indicators

Research Demand Index: 10.77

Study Types

Related Drugs (33)

Related Conditions (27)